Hussein A. Abbas, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Hussein A. Abbas
Dr. Abbas sees patients with hematologic malignancies, with a special focus on patients with systemic mastocytosis (SM) and acute myeloid leukemia (AML). His research builds on previous findings of the complex dynamics of leukemic cells within their immune microenvironment. By leveraging integrative high dimensional and multiplatform genomic, transcriptomic, and epigenomic data emerging from patients receiving treatment for hematologic malignancies, the research aims to uncover biomarkers and mechanisms of response/resistance to therapies.
Present Title & Affiliation
Primary Appointment
Adjunct Assistant Professor, Division of Cancer Medicine, University of Texas School of Biomedical Informatics, Houston, TX
Regular Member, University of Texas Graduate School of Biomedical Sciences, Houston, TX
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Member, Cancer Biology Program in the University of Texas Graduate School of Biomedical Sciences, Houston, TX
Member, Immunology Program in the University of Texas Graduate School of Biomedical Sciences, Houston, TX
Adjunct Assistant Professor, University of Texas School of Biomedical Informatics, Houston, TX
Regular Member, University of Texas Graduate School of Biomedical Sciences, Houston, TX
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | American University of Beirut, Beirut, LB, MD |
| 2010 | UT MD Anderson Cancer Center and Health Science Center, Houston, Texas, US, Cancer Biology and Genes & Development, Ph.D |
| 2006 | Lebanese American University, Beirut, LB, Biology, B.Sc |
| 2003 | Beirut Baptist School, Beirut, LB, Mathematics, Baccalaureate |
Postgraduate Training
| 2018-2021 | Clinical Fellowship, Medical Oncology Program, MD Anderson Cancer Center, Houston, Texas |
| 2016-2018 | Clinical Residency, Internal Medicine Residency, Johns Hopkins Hospital, Baltimore, Maryland |
| 2014-2016 | Research Fellowship, Bioinformatics Focus, MD Anderson Cancer Center, Houston, Texas |
Board Certifications
| 2022 | Board Certified in American Board of Hematology |
| 2022 | Board Certified in American Board of Medical Oncology |
| 2019 | Board Certified in American Board in Internal Medicine |
Experience & Service
Academic Appointments
Member, Quantitative Science Program Affiliation in GSBS, Houston, TX, 2022 - 2023
Part-time Assistant Professor, Department of Division of Natural Science, Lebanese American University, Beirut, 2010 - 2012
Part-time Assistant Professor, Department of Faculty of Health Sciences, American University of Science and Technology, Beirut, 2010 - 2013
Administrative Appointments/Responsibilities
Council Member, Advisory Council for the Doctorate Program of McWilliams School of Biomedical Informatics Health Informatics (DHI), 2024 - Present
Chair, Odyssey Fellowship Committee, MD Anderson Cancer Center, Houston, TX, 2024 - Present
Elected Member, MD Anderson Cancer Center Faculty Senate, Houston, TX, 2024 - Present
Co-Chair, Odyssey Fellowship Committee, MD Anderson Cancer Center, Houston, TX, 2023 - 2024
Interviewer, Interview Candidates for UT MD Anderson Cancer Center GSBS, Houston, TX, 2023 - Present
Council Member, Industry Advisory Council at McWilliams School of Biomedical Informatics at UTHealth, Houston, TX, 2023 - Present
Student Scholarship Committee, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2023 - Present
Committee Member, Odyssey Fellowship Committee, MD Anderson Cancer Center, Houston, TX, 2022 - Present
Trainee Research Council Member, American Society of Hematology, Washington, DC, 2020 - 2022
Member of Education Committee, Department of MD Anderson Cancer Center, Hematology/Oncology Fellowship, Houston, TX, 2019 - 2021
Other Appointments/Responsibilities
Associate Faculty, Hematology Section, F1000 Prime, Houston, TX, 2013 - 2016
Founding President and Board Member, Toufoula Organization, Beirut, 2006 - 2008
Institutional Committee Activities
Chair, Odyssey Fellowship Committee, 2024 - Present
Committee Member, GSBS Student Scholarship Committee (SSC), 2023 - Present
Advisory Committee Member, Epigenomics Profiling Core, 2023 - Present
Co-Chair, Odyssey Fellowship Committee, 2023 - 2024
Member, Odyssey Fellowship Committee, 2022 - Present
Member, Clinic to ACCC Handoff Institutional Committee, 2022 - 2023
Member, ICU Utilization and Goals of Care, 2021 - 2023
Education Committee Member, Medical Oncology Fellowship, 2019 - 2021
Honors & Awards
| 2025 - 2029 | Career Development Award, Department of Defense Peer Reviewed Cancer Research Program |
| 2025 - 2028 | Career Development Award, American Society of Clinical Oncology Conquer Cancer Foundation |
| 2022 - 2027 | Physician Scientist Scholar Award, MD Anderson Cancer Center |
| 2022 | Comprehensive Cancer Center New Faculty Award, MD Anderson Cancer Center |
| 2021 | Waun Ki Hong Award for Achievement in Basic Science Research, Medical Oncology Fellowship Program, UT MD Anderson Cancer Center, Houston, USA |
| 2021 | American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award |
| 2020 | Society for Immunotherapy of Cancer Annual Meeting Trainee Award |
| 2020 | American Society of Hematology Annual Meeting Trainee Award |
| 2020 | Kimberley Patterson Fellowship for Excellence in Leukemia Research, UT MD Anderson Cancer Center, Houston, USA |
| 2019 - 2020 | Young Investigator Award – Adaptive Biotechnologies |
| 2019 - 2021 | T32 NIH Trainee Grant for Research in Medical Oncology |
| 2014 - 2016 | Odyssey Scholar Award; UT MD Anderson Cancer Center, Houston, USA |
| 2012 - 2014 | Merit scholarship from American University of Beirut School of Medicine for Med-III and Med-IV years, Beirut, Lebanon |
| 2011 - 2012 | Merit scholarship from George Nassim Khoriaty Foundation (GNKF) for the second academic year (Med-II) at the Lebanese American University School of Medicine, Byblos, Lebanon |
| 2010 - 2011 | Merit scholarship from Lebanese American University for the first academic year (Med-I) at the Lebanese American University School of Medicine, Byblos, Lebanon |
| 2009 | Gordon Research Conference: Stem Cells and Cancer best poster award; Les Diablerets, Switzerland |
| 2009 | William A. and Madelyn Welder Smith Foundation Fellowship; UT Graduate School of Biomedical Sciences & MD Anderson Cancer Center, Houston, USA, 2009 |
| 2008 - 2009 | Floyd Haar Endowed Memorial Research Award; UT Graduate School of Biomedical Sciences & MD Anderson Cancer Center, Houston, USA |
| 2004 - 2006 | Scholarship from Lebanese American University in Beirut to pursue B.Sc. studies in biology, Beirut, Lebanon, 2004-2006 |
| 2003 - 2006 | High Distinction, Lebanese American University during Fall 2003, Spring 2004, Fall 2004, Spring 2005, Fall 2005 and Spring 2006 semesters, Beirut, Lebanon |
| 2003 - 2006 | Student’s Honor Society of the Lebanese American University for 2003-2004, 2004-2005 and 2005-2006 academic years, Beirut, Lebanon, 2003-2006 |
| 2003 | Recognition from Rafic Al-Hariri Association for Lebanese Baccalaureate exams scores in General Sciences (emphasis on Mathematics), Beirut, Lebanon, 2003 |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant, 2025. e-Pub 2025. PMID: 40217110.
- Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Bravo GM, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40198272.
- Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo Y, Garza AI, Root JL, Qiao W, Arruda A, Ivo Veletic MD, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes. Blood, 2025. e-Pub 2025. PMID: 40179376.
- Kugler E, Dasdemir E, Bataller A, Wang B, DiNardo CD, Daver N, Yilmaz M, Short NJ, Borthakur G, Kadia TM, Sasaki K, Hammond D, Bazinet A, Irajizad E, Thakral B, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leuk Lymphoma, 2025. e-Pub 2025. PMID: 40164144.
- Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Gupta V, Fiskus W, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou EP, Bhalla KN, Zhou D, Mead AJ, Rampal RK, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva MY. Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML. Blood, 2025. e-Pub 2025. PMID: 40163809.
- Abbas HA, Jen W, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia, 2025. e-Pub 2025. PMID: 40000842.
- Jen W, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver NG, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Karrar OS, Pierce S, Kantarjian HM, Short NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv 9(4):783-792, 2025. e-Pub 2025. PMID: 39631072.
- Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol. e-Pub 2025. PMID: 39921561.
- Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica. e-Pub 2024.
- Jen W, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662. e-Pub 2024. PMID: 39584789.
- Li Z, Li R, Ganan-Gomez I, Abbas HA, Garcia-Manero G, Sun W. Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis. Sci Rep 14(1):24152, 2024. e-Pub 2024. PMID: 39406835.
- Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. e-Pub 2024. PMID: 39303729.
- Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Nunez Cortes AK, Kaplan M, Acharya S, Shaim H, Xu AC, Wu M, Ensley E, Fang D, Banerjee PP, Garcia LM, Tiberti S, Lin P, Rafei H, Munir MN, Moore M, Shanley M, Mendt M, Kerbauy LN, Liu B, Biederstädt A, Gokdemir E, Ghosh S, Kundu K, Reyes-Silva F, Jiang XR, Wan X, Gilbert AL, Dede M, Mohanty V, Dou J, Zhang P, Liu E, Muniz-Feliciano L, Deyter GM, Jain AK, Rodriguez-Sevilla JJ, Colla S, Garcia-Manero G, Shpall EJ, Chen K, Abbas HA, Rai K, Rezvani K, Daher M. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci Transl Med. e-Pub 2024. PMID: 39259809.
- Narayanan N, Marvin-Peek J, Abouelnaaj MK, Majid D, Wang B, Brown BD, Qiu Y, Kornblau SM, Abbas HA. Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia. J Proteome Res 23(7):2495-2504, 2024. e-Pub 2024. PMID: 38829961.
- Marvin-Peek J, Sasaki K, Kontoyiannis DP, Adachi J, Ohanian M, Takahashi K, Issa GC, Kornblau S, Abbas HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series. Front. Med 11, 2024. e-Pub 2024.
- Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract, 2024. e-Pub 2024. PMID: 39013130.
- Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
- Radpour R, Simillion C, Wang B, Abbas HA, Riether C, Ochsenbein AF. IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion. Blood 144(8):888-903, 2024. e-Pub 2024. PMID: 38941612.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. e-Pub 2024. PMID: 38695144.
- Root JL, Desai PN, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay S, Alfayez M, Matthews J, Pierce S, Reville PK, Daver N, Abbas HA. Single-Cell CD4 and CD8 T Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Res Commun 4(3):671-681, 2024. e-Pub 2024. PMID: 38391202.
- Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
- Guo S, Mohan GS, Wang B, Li T, Daver N, Zhao Y, Reville PK, Hao D, Abbas HA. Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer 12(2):e008318, 2024. e-Pub 2024. PMID: 38418394.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Kadia TM, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
- Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
- Fan H, Wang F, Zeng A, Murison A, Tomczak K, Hao D, Jelloul FZ, Wang B, Barrodia P, Liang S, Chen K, Wang L, Zhao Z, Rai K, Jain AK, Dick J, Daver N, Futreal A, Abbas HA. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol 6(1):765, 2023. e-Pub 2023. PMID: 37479893.
- Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Beird HC, Yin CC, Khoury JD, Pierce SR, Abbas HA, Zhao L, Skwarska A, Qazilbash MH, Konopleva MY, Futreal A, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(10):2000-2003, 2023. e-Pub 2023. PMID: 36689729.
- Lee SE, Wang F, Grefe M, Trujillo-Ocampo A, Ruiz-Vasquez W, Takahashi K, Abbas HA, Borges P, Antunes DA, Al-Atrash G, Daver N, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res 29(10):1938-1951, 2023. e-Pub 2023. PMID: 36988276.
- Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2023. PMID: 35405739.
- Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Abbas HA, Woodman SE, Nates JL, Collaborators DT. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19. Mayo Clin Proc 98(3):451-457, 2023. e-Pub 2023. PMID: 36868753.
- Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornhäuser M, Gojo I, Luznik L. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest 132(21), 2022. e-Pub 2022. PMID: 36099049.
- Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
- Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
- Pabon CM, Abbas HA, Konopleva M. Acute myeloid leukemia: therapeutic targeting of stem cells. Expert Opin Ther Targets 26(6):1-10, 2022. e-Pub 2022. PMID: 35634856.
- Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med 28(6):1212-1223, 2022. e-Pub 2022. PMID: 35618837.
- Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. Author Correction: ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun 13(1):1717, 2022. e-Pub 2022. PMID: 35338160.
- Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nat Commun 13(1):614, 2022. e-Pub 2022. PMID: 35105868.
- Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402-3410, 2021. e-Pub 2021. PMID: 34380367.
- Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
- Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. e-Pub 2021. PMID: 34555853.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Abbas HA, Reville PK, Jiang X, Yang H, Reuben A, Im JS, Little L, Sinson JC, Chen K, Futreal A, Garcia-Manero G. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Front Immunol 12:659625, 2021. e-Pub 2021. PMID: 33912187.
- Abbas HA, Mohanty V, Wang R, Huang Y, Liang S, Wang F, Zhang J, Qiu Y, Hu CW, Qutub AA, Dail M, Bolen CR, Daver N, Konopleva M, Futreal A, Chen K, Wang L, Kornblau SM. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Front Oncol 11:705627, 2021. e-Pub 2021. PMID: 34422660.
- Bui NHB, Napoli M, Davis AJ, Abbas HA, Rajapakshe K, Coarfa C, Flores ER. Spatiotemporal Regulation of ?Np63 by TGFβ-Regulated miRNAs Is Essential for Cancer Metastasis. Cancer Res 80(13):2833-2847, 2020. e-Pub 2020. PMID: 32312834.
- Davis AJ, Tsinkevich M, Rodencal J, Abbas HA, Su XH, Gi YJ, Fang B, Rajapakshe K, Coarfa C, Gunaratne PH, Koomen JM, Tsai KY, Flores ER. TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. Cancer Res 80(12):2484-2497, 2020. e-Pub 2020. PMID: 32156775.
- Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res 26(4):892-901, 2020. e-Pub 2020. PMID: 31694833.
- Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, ESJM DB, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl 13(4):e1800133, 2019. e-Pub 2019. PMID: 30650251.
- Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
- Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res 11:8817-8828, 2019. e-Pub 2019. PMID: 31632141.
- Rafei RE, Abbas HA, Alameddine H, Bizri AA, Melki I, Yunis KA. Assessing the Risk of Having Small for Gestational Age Newborns Among Lebanese Underweight and Normal Pre-pregnancy Weight Women. Matern Child Health J 22(1):130-136, 2018. e-Pub 2018. PMID: 28780682.
- Abbas HA, Bui NHB, Rajapakshe K, Wong J, Gunaratne P, Tsai KY, Coarfa C, Flores ER. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78(2):451-462, 2018. e-Pub 2018. PMID: 29180475.
- Ezzeddine D, Hamadi C, Abbas HA, Nassar A, Abiad M, Ghazeeri G. Prevalence and Correlation of Hypothyroidism With Pregnancy Outcomes Among Lebanese Women. J Endocr Soc 1(5):415-422, 2017. e-Pub 2017. PMID: 29264496.
- Su X, Napoli M, Abbas HA, Venkatanarayan A, Bui NHB, Coarfa C, Gi YJ, Kittrell F, Gunaratne PH, Medina D, Rosen JM, Behbod F, Flores ER. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene 36(17):2377-2393, 2017. e-Pub 2017. PMID: 27869165.
- Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 64(1):188-196, 2017. e-Pub 2017. PMID: 27576370.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Ghazeeri G, Zebian D, Nassar AH, Harajly S, Abdallah A, Hakimian S, Skaiff B, Abbas HA, Awwad J. Knowledge, attitudes and awareness regarding fertility preservation among oncologists and clinical practitioners in Lebanon. Hum Fertil (Camb) 19(2):127-33, 2016. e-Pub 2016. PMID: 27376977.
- Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. e-Pub 2016. PMID: 27300436.
- Inati A, El Hachem Y, Tawk S, Kassm SA, Abbas HA. Pediatric Immune Thrombocytopenia in Lebanon: Treatment and Predictors of Outcome. Pediatr Blood Cancer 63(2):375-6, 2016. e-Pub 2016. PMID: 26313008.
- Batley NJ, Nasreddine Z, Chami A, Zebian D, Bachir R, Abbas HA. Cynicism and other attitudes towards patients in an emergency department in a middle eastern tertiary care center. BMC Med Educ 16:36, 2016. e-Pub 2016. PMID: 26823070.
- El Rafei R, Abbas HA, Charafeddine L, Nakad P, Al Bizri A, Hamod D, Yunis KA. Association of Pre-Pregnancy Body Mass Index and Gestational Weight Gain with Preterm Births and Fetal Size: an Observational Study from Lebanon. Paediatr Perinat Epidemiol 30(1):38-45, 2016. e-Pub 2016. PMID: 26469281.
- Ghazeeri G, Abbas HA, Skaff B, Harajly S, Awwad J. Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. J Endocrinol Invest 38(6):643-51, 2015. e-Pub 2015. PMID: 25722221.
- Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62(2):371-9, 2015. e-Pub 2015. PMID: 25281858.
- Inati A, Noun P, Kabbara N, Salloum C, Kmeid M, Sadek M, Abbas HA, Kahale M. A multicenter study on the Lebanese experience with hereditary spherocytosis. Pediatr Blood Cancer 61(10):1895-6, 2014. e-Pub 2014. PMID: 24590699.
- Inati A, Kahale M, Perrine SP, Chui DH, Taher AT, Koussa S, Abi Nasr T, Abbas HA, Ghalie RG. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol 164(3):456-8, 2014. e-Pub 2014. PMID: 24224649.
- Khoriaty E, Halaby R, Berro M, Sweid A, Abbas HA, Inati A. Incidence of sickle cell disease and other hemoglobin variants in 10,095 Lebanese neonates. PLoS One 9(9):e105109, 2014. e-Pub 2014. PMID: 25180595.
- Ghazeeri G, Fakih A, Abbas HA, Harajly S, Awwad J. Anxiety, cognitive, and depressive assessment in adolescents with polycystic ovarian syndrome: a pilot study. J Pediatr Adolesc Gynecol 26(5):269-73, 2013. e-Pub 2013. PMID: 23849090.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas H, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
- Salman M, Khoury NJ, Khalifeh I, Abbas HA, Majdalani M, Abboud M, Muwakkit S, Solh HE, Saab R. Congenital infantile fibrosarcoma: Association with bleeding diathesis. Am J Case Rep 14:481-5, 2013. e-Pub 2013. PMID: 24265847.
- Inati A, Akouri G, Abbas HA. A rare aggravation of severe mucositis post chemotherapy in a child with acute lymphoblastic leukemia. F1000Res 2:196, 2013. e-Pub 2013. PMID: 24555093.
- Inati A, Abbas HA, Boumitri C, Tecle N. Prevalence of glucose-6-phosphate dehydrogenase deficiency among neonates at a tertiary care centre in Lebanon. J Med Screen 19(2):103-4, 2012. e-Pub 2012. PMID: 22554801.
- Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 10(19):3257-62, 2011. e-Pub 2011. PMID: 21957490.
- Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 7(5):606-17, 2010. e-Pub 2010. PMID: 21040902.
Other Articles
- Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan C, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb E, Issa GC Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. PMID: 39179671.
- Chomczyk M, Gazzola L, Dash S, Firmanty P, George BS, Mohanty V, Abbas HA, Baran N Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment. Front Pharmacol, 2024. PMID: 39161899.
- Abbas HA, Wierda WG Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021. PMID: 34055635.
- Wilson NR, Abbas HA, Kala J Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices. Am J Med 134(3):e147-e149, 2020. PMID: 33121958.
- Abbas HA, Amini B, Wang WL, Ravi V Maneuvering the Management of a Rare Case of Primary Undifferentiated Cardiac Sarcoma. Am J Case Rep 21:e918878, 2020. PMID: 32198341.
- Abbas HA, Han X Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia. N Engl J Med 380(24):2360, 2019. PMID: 31189039.
- Abiad F, Awwad J, Abbas HA, Zebian D, Ghazeeri G Management of weight loss in obesity-associated male infertility: a spotlight on bariatric surgery. Hum Fertil (Camb) 20(4):227-235, 2017. PMID: 28460579.
- Inati A, Mansour AG, Sabbouh T, Amhez G, Hachem A, Abbas HA Transfusion Therapy in Children With Sickle Cell Disease. J Pediatr Hematol Oncol 39(2):126-132, 2017. PMID: 27509379.
- Inati A, Noureldine MA, Mansour A, Abbas HA Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int 2015:813098, 2015. PMID: 25834825.
- Abbas HA, Yunis K The effect of consanguinity on neonatal outcomes and health. Hum Hered 77(1-4):87-92, 2014. PMID: 25060272.
- Inati A, Abbas HA, Korjian S, Daaboul Y, Harajeily M, Saab R A case of Pitt-Hopkins syndrome with absence of hyperventilation. J Child Neurol 28(12):1698-701, 2013. PMID: 23248353.
- Inati A, Tourjuman O, Bizri D, Dhayni R, Abbas HA, Tfaili H, Akouri G, Beydoun A A rare case of Moyamoya syndrome in a β-thalassemia major patient. Blood Cells Mol Dis 51(3):149-50, 2013. PMID: 23735661.
- Abbas HA, Kahale M, Hosn MA, Inati A A review of acute chest syndrome in pediatric sickle cell disease. Pediatr Ann 42(3):115-20, 2013. PMID: 23458871.
- Inati A, Abbas HA, Al-Danaf J, Souaid M, Kahale M, Koussa S, Abou Nasr T, Davis L, Luo HY, Chui DH Identification of the first mutation in a BRE motif of the β-globin gene and its inheritance with two other α-globin gene mutations in a Lebanese family. Hemoglobin 37(2):171-5, 2013. PMID: 23470150.
- Post SM, Pant V, Abbas H, Quintás-Cardama A Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget 1(3):168-74, 2010. PMID: 21301048.
Editorials
- Zhao L, Zhang J, Xu L, Abbas HA. Novel Cancer Immunotherapies and Antitumor Immunity. J Immunol Res, 2019.
Abstracts
- Montalban-Bravo G, Loghavi S, Almanza E, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa G, Abbas H, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Kanagal-Shamanna R, Wang S, Wang W, Fang H, Tang G, Pierce S, Ramos CB, Medeiros J, Kantarjian H, Garcia-Manero G. Spectrum And Clinical Implications Of Extramedullary Manifestations In Chronicmyelomonocytic Leukemia 8(Issue S1):1371 - 1372, 2024. e-Pub 2024.
- Jen W, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Short N, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado-Valero Y, Pemmaraju N, Ferrajoli A, Reville P, Swaminathan M, Ohanian M, Abbas H, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva M, Mullin J, Pierce S, Kantarjian H, DiNardo C. Flag-Ida + Venetoclax (Ven) In Newly Diagnosed (Nd) Or Relapsed / Refractory (Rr) Aml 8(Issue S1):79-80, 2024. e-Pub 2024.
- Farhat A, Sasaki K, Short N, Cuglievan B, Loghavi S, Patel K, Tang G, Yilmaz M, Montalban-Bravo G, Abbas H, Hammond D, Pemmaraju M, Daver N, DiNardo C, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa G. Clinical Characteristics Of Rare Genetic Alterations Associated With Upregulation Of Hoxgenes In Adults With Acute Leukemia 8(Issue S1):1004-1005, 2024. e-Pub 2024.
- Kugler E, Desdemir E, Wang B, Bataller A, DiNardo C, Daver N, Yilmaz M, Short N, Kadia T, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas H. Mutation Patterns And Prognostic Implications In Acute Myeloid Leukemia With Chromosomal7 Deletions 8(Issue S1):1006 - 1007, 2024. e-Pub 2024.
- Kugler E, Desdemir E, Wang B, Torralba AB, DiNardo CD, Daver N, Yilmaz M, Short N, Kadia T, Sasaki K, Bazinet A, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation patterns and Prognostic implications in Acute Myeloid Leukemia with chromosomal 7 deletions 42(16), 2024. e-Pub 2024.
- Desai PN, Wang B, Reville PK, Jelloul FZ, Borges P, Senapati J, Castillo M, Gunaratne P, Pemmaraju N, Kadia TM, Ravandi F, Garcia-Manero G, Daver N, Abbas HA. Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance(64), 2023. e-Pub 2023.
- Root JL Desai PN, Reville PK, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay SG, Alfayez M, Matthews J, Pierce S Daver N Abbas HA. Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy(1584), 2023. e-Pub 2023.
- Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Alvarado Valero Y, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment(1480), 2023. e-Pub 2023.
- Arani N, Almanza E, Bataller A, DiNardo CD, Ravandi F, Daver N, Pemmaraju N, Yilmaz M, Maiti A, Reville PK, Loghavi S, HA <, Garcia-Manero G, Short NJ, Kantarjian HM, Kadia TM. Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens(4236), 2023. e-Pub 2023.
- Bijender Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Shanley M, Acharya S, Mendt MC, Lin P, Biederstädt A, Rafei H, Banerjee P, Mohanty V, Shaim H, Dede M, Garcia LM, Kerbauy LN, Nunez Cortes AK Miao Q, Dou J, Reyes FS, Guo X, Kaplan M, Ang S, Jiang XR, Liu E, Liu B, PhD, Champlin RE, MD, Kantarjian H, Marin D, Chen K, Abbas HA, Shpall EJ, Kunal Rai K, Rezvani K Daher M. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies(2088), 2023. e-Pub 2023.
- Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA Ekmekcioglu S, Sasaki K, Garcia MB Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies(2796), 2023. e-Pub 2023.
- Masarova L, Kantarjian HM, Pemmaraju N, Abbas HA, Bose P, Swaminathan M, Pierce S, Sasaki K, Yilmaz M, Short NJ, Daver N, Borthakur G, Garcia-Manero G, Ohanian M, Bhalla KN, DiNardo CD, Kadia TM. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)(4264), 2023. e-Pub 2023.
- Khasawneh A, Paran FJ, Oyama R, Maiti A, Abbas HA, Wang B, Desai PN, Hayes K, Harman JR, Su X, DiNardo CD, Andreeff M, Milne TA, Konopleva MY, Tabe Y. Molecular Profiling of Response and Resistance to Venetoclax–Decitabine Therapy in Acute Myeloid Leukemia(4159), 2023. e-Pub 2023.
- Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Alvarado Valero Y, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA, Jabbour E, Andreeff M, Ravandi F, Tidwell RSS, Wang X, Konopleva MY, Garcia-Manero G, Kantarjian HM, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update(968), 2023. e-Pub 2023.
- Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Alvarado Valero Y, Montalban-Bravo G, Maiti A, HA <, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment(723), 2023. e-Pub 2023.
- Wang B, Ly C, Dasdemir E, Jelloul FZ, Desai PN, Borges P, Root JL, Tang G, Gunaratne P, Basu S, Jindal S, Chen Y, Wani KM, Lazar AJ, Sharma P, Reville PK, Abbas HA. Characterizing Inferred Functional and Phenotypical States of Newly Diagnosed Acute Myeloid Leukemia from Single Cell Transcriptomic Profiling(2938), 2023. e-Pub 2023.
- Daver N, MD, Senapati J, MD, MBBS, DM, Maiti A, MBBS, Loghavi S, MD, Kadia TM, MD, DiNardo CD, MD, MSCE, Pemmaraju N, MD, Jabbour E, MD, Montalban-Bravo G, MD, Tang G, MD, PhD, Sasaki K, MD, Borthakur G, MD, Yilmaz M, MD, Alvarez J, BSN, Pierce SA, BSN, BA, Nogueras González GM, MPH, Ning J, Issa GC, MD, Andreeff M, MD, PhD, Abbas HA, Ravandi F, MD, Garcia-Manero G, MD, Kantarjian H, MD. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML(61), 2022. e-Pub 2022.
- Macaron W, MD, MSc, Ravandi F, MD, Kadia TM, MD, DiNardo CD, MD, MSCE, Issa GC, MD, Daver N, MD, Wang SA, MD, Jorgensen JL, MD, PhD, Patel K, MD, PhD, Loghavi S, MD, Konopleva M, MD, PhD, Yilmaz M, MD, Jabbour E, MD, Maiti A, MBBS, Abbas HA, Shpall EJ, MD, Popat UR, MD, Alatrash G, PhD, DO, Pierce SA, BSN, BA, Kantarjian H, MD, Short N, MD. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission(224), 2022. e-Pub 2022.
- Kantarjian, MD, Arani N, MD, Popat UR, MD, DiNardo CD, MD, MSCE, Daver N, MD, Yilmaz M, MD, Abbas HA, Short N, MD, Issa GC, MD, Jabbour E, MD, Pierce SA, BSN, BA. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III(732), 2022. e-Pub 2022.
- Atluri H, MD, Maiti A, MBBS, Sasaki K, MD, Daver N, MD, Alvarado Y, MD, Hossain MF, MD, MS, Wang X, MS, Pemmaraju N, MD, Takahashi K, MD, PhD, Borthakur G, MD, Ferrajoli A, Short N, MD, Abbas HA, Ravandi F, MD, Jabbour E, MD, Andreeff M, MD, PhD, Garcia-Manero G, MD, Kantarjian H, MD, Konopleva M, MD, PhD, DiNardo CD, MD, MSCE. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia(2746), 2022. e-Pub 2022.
- Reville PK, MD, MPH, Kantarjian H, MD, Borthakur G, MD, Yilmaz M, MD, Daver N, MD, Short N, MD, DiNardo CD, MD, MSCE, Kornblau SM, MD, Pemmaraju N, MD, Jain N, MD, Alvarado Y, MD, Bose P, MD, Jabbour E, MD, Chien KS, MD, Abbas HA, Masarova L, MD, Wang SA, MD, S Tidwell RS, MS, Andreeff M, MD, PhD, Garcia-Manero G, MD, Konopleva M, MD, PhD, Ravandi F, MD, Kadia TM, MD. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance(616), 2022. e-Pub 2022.
- Desai P, MSc, Wang B, PhD, Jelloul FZ, MD, Alatrash G, PhD, DO, Baran N, MD, PhD, Deng Q, PhD, Green MR, PhD, Daver N, MD, Konopleva M, MD, PhD, Futreal A, PhD, Hao D, Abbas HA. Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes(4119), 2022. e-Pub 2022.
- Wang B, PhD, Jelloul FZ, MD, Borges P, Desai P, MSc, Tang G, MD, PhD, Konopleva M, MD, PhD, Baran N, MD, PhD, Green MR, PhD, Deng Q, PhD, Daver N, MD, Futreal A, PhD, Hao D, Abbas HA. Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients(2790), 2022. e-Pub 2022.
- Deng Q, Green MR, Daver N, Konopleva M, Futreal A, Hao D, Abbas HA. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II(317), 2022. e-Pub 2022.
- Jabbour E, MD, Kadia TM, MD, Short N, MD, DiNardo CD, MD, MSCE, Borthakur G, MD, Abbas HA, Pemmaraju N, MD, Garcia-Manero G, MD, Ravandi F, MD, Kantarjian H, MD, Yilmaz M, MD. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I(613), 2022. e-Pub 2022.
- Wang X, MS, Pemmaraju N, MD, Takahashi K, MD, PhD, Borthakur G, MD, Ferrajoli A, Short N, MD, Abbas HA, Ravandi F, MD, Jabbour E, MD, Andreeff M, MD, PhD, Garcia-Manero G, MD, Kantarjian H, MD. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II(615), 2022. e-Pub 2022.
- Venugopal S, MD, MS, Loghavi S, MD, Routbort M, MD, PhD, Jelloul FZ, MD, Kanagal-Shamanna R, MD, Pierce SA, BSN, BA, Issa GC, MD, Abbas HA, Sasaki K, MD, Takahashi K, MD, PhD, Daver N, MD, Ravandi F, MD, Kantarjian H, MD, DiNardo CD, MD, MSCE. Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies(2814), 2022. e-Pub 2022.
- Reville PK, MD, MPH, Kantarjian H, MD, Borthakur G, MD, Yilmaz M, MD, Daver N, MD, Short N, MD, DiNardo CD, MD, MSCE, Kornblau SM, MD, Pemmaraju N, MD, Jain N, MD, Alvarado Y, MD, Bose P, MD, Jabbour E, MD, Chien KS, MD, Abbas HA, Masarova L, MD, Wang SA, MD, S Tidwell RS, MS, Andreeff M, MD, PhD, Garcia-Manero G, MD, Konopleva M, MD, PhD, Ravandi F, MD, Kadia TM, MD. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome(709), 2022. e-Pub 2022.
- Abbas HA, Ayoub E, PhD, Sun H, Kanagal-Shamanna R, MD, Short N, MD, Issa GC, MD, Yilmaz M, MD, Pierce SA, BSN, BA, Rivera D, MD, Cham B, Wing S, Li Z, PhD, Hammond D, MD, Jabbour E, MD, Borthakur G, MD, Garcia-Manero G, MD, Andreeff M, MD, PhD, Daver N, MD, Kadia TM, MD, Konopleva M, MD, PhD, DiNardo CD, MD, MSCE, Ravandi F, MD. Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment(2701), 2022. e-Pub 2022.
- Senapati J, MD, MBBS, DM, Short N, MD, Maiti A, MBBS, Abbas HA, Daver N, MD, Pemmaraju N, MD, Pierce SA, BSN, BA, Chien KS, MD, Sasaki K, MD, Hammond D, MD, Borthakur G, MD, Ravandi F, MD, Kantarjian H, MD, DiNardo CD, MD, MSCE. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia(596), 2022. e-Pub 2022.
- Haddad F, MD, Medawar G, Kanagal-Shamanna R, MD, Alvarez H, Loghavi S, MD, Daver N, MD, Pierce SA, BSN, BA, Jabbour E, MD, Kadia TM, MD, Short N, MD, DiNardo CD, MD, MSCE, Borthakur G, MD, Abbas HA, Pemmaraju N, MD, Garcia-Manero G, MD, Ravandi F, MD, Kantarjian H, MD, Yilmaz M, MD. Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)(1384), 2022. e-Pub 2022.
- Bazinet A, MD, Kantarjian H, MD, Arani N, MD, Popat UR, MD, DiNardo CD, MD, MSCE, Daver N, MD, Yilmaz M, MD, Abbas HA, MD, PhD, Short N, MD, Issa GC, MD, Jabbour E, MD, Pierce SA, BSN, BA, Chen J, Garcia R, Konopleva M, MD, PhD, Garcia-Manero G, MD, Alousi AM, MD, Shpall EJ, MD, Champlin RE, MD, Borthakur G, MD, Ravandi F, MD, Kadia TM, MD. Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years(2125), 2022. e-Pub 2022.
- Daver N, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour EJ, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, Nogueras González GM, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian AH. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML, 2021. e-Pub 2021.
- Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, Dinardo C, Bueso-Ramos C, Andreeff M, Short N, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma, 2020. e-Pub 2020.
- Daver NG, Basu S, Garcia-Manero G, Abbas HA, Konopleva M, Kadia TM, DiNardo CD, Borthakur G, Alfayez M, Alotaibi A, Pemmaraju N, Jabbour EJ, Pierce SA, Brandt M, Takahashi K, Ning J, Kornblau SM, Sasaki K, Yilmaz M, Issa G, Short N, Matthews J, Flores W, Andreeff M, Cortes JE, Ravandi F, Allison JP, Sharma P, M Kantarjian AH, MD. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response, 2020. e-Pub 2020.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Takahashi K, Ning J, Ding M, Matthews JA, Little L, Zhang J, Basu S, DiNardo CD, Kadia TM, Ravandi F, Borthakur G, Konopleva M, Garcia-Manero G, Green MR, Alatrash G, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Futreal P, Daver AN. Single-cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy, 2020. e-Pub 2020.
- Abbas HA, Bao Bui NH, Rajapakshe K, Wong J, Gunaratne P, Tsai KY, Coarfa C, Flores ER. Agnostic Transcriptional Profiling of The Cancer Genome Atlas Data Identifies Distinct and Cooperative Role of TP63 Isoforms in Renal Cancer Subtypes That Drive Progression and Predict Clinical Outcomes, 2019. e-Pub 2019.
- Abbas HA, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, Daver NG. RNA based immune signatures may Predict Responses to PD-1 Inhibition and Azacitidine Treatment in Acute Myeloid Leukemia (AML): A subset analysis of a Phase 2 Study, 2019. e-Pub 2019.
- Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraju N, Kadia TM, DiNardo CD, Cortes JE, Ravandi F, Abbas HA, Basu S, Jabbour E, Pierce SA, Estrov ZE, Takahashi K, Ning J, Kornblau SM, Sasaki K, Masarova L, Flores W, Allison JP, Sharma P, Kantarjian HM. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study, 2019. e-Pub 2019.
- Abbas HA, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, Daver NG. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): a subset analysis of a phase 2 study, 2019. e-Pub 2019.
- Abbas HA, Coarfa C, Flores E. Mining The Cancer Genome Atlas for TP53 Family Transcriptional Regulatory Networks, 2015. e-Pub 2015.
- Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutant tumors, 2015. e-Pub 2015.
- Inati A, Farah S, Khammash D, Kahale M, Abbas HA, Azar G. Ophthalmologic complications in a sickle cell disease cohort in North Lebanon, 2014. e-Pub 2014.
- Inati A, Gaziev J, Korjian S, Daaboul Y, Kahale M, Abbas HA, Paciaroni K, Angelis GD, Taher A, Suzan Koussa TAN, Lucarelli AG. A Lebanese-Italian Collaborative Initiative on Bone Marrow Transplantation in Pediatric Patients with β-Thalassemia Major, 2013. e-Pub 2013.
- Inati A, Kahale M, Perrine S, ATaher, Koussa S, Abbas HA, Nader T, G Ghalie AR. A phase 2 trial of the hemoglobin inducer HQK-1001 (2,2-dimethylbutyrate, sodium salt) in nontransfusion-dependent β-Thalassemia (study LB-04 THAL), 2013. e-Pub 2013.
- Khoriaty E, Halaby R, Berro M, Sweid A, Abbas HA, Inati A. Neonatal screening program for inherited haemoglobin disorders in public hospitals across, 2013. e-Pub 2013.
- Ghaziri G, Fakih A, Abbas HA, Harajly S, Awwad J. Anxiety, Cognitive and Depressive Assessment in Adolescents with Polycystic Ovary Syndrome: A Pilot Study, 2013. e-Pub 2013.
- Inati A, Abbas HA, Souaid M, Koussa S, Taher A, Nasr TA, Chui AD. Identification of the First Mutation in BRE Motif of β-globin & Its Polygenic Inheritance with Two Other α-globin Mutations in Patients of the Same Family, 2012. e-Pub 2012.
- Khoriaty E, Halaby R, Abbas HA, Sweid A, Berro M, Inati AA. Neonatal Screening for Hemoglobinopathies in Public Hospitals across Lebanon, 2012. e-Pub 2012.
- Abbas HA, Coskun S, Sills T, You M, Hirschi KK, Lozano G. Mdm2 regulation of ROS-activated p53 is indispensable for survival of hematopoietic progenitor and stem cells, 2009. e-Pub 2009.
- El Ahdab SY, Castoro R, Abbas HA, Ahmed S, Jelinek J, Issa J. Epigenetic profiling of apoptotic genes in leukemia and colon cancer, 2008. e-Pub 2008.
- Ahdab SE, Castoro R, Abbas HA, Ahmed S, Jelinek J, Issa J. Methylation Profiling of Apoptotic Genes in Leukemia Cell Lines and Patients, 2007. e-Pub 2007.
- Bouligny IM, Kantarjian HM, Yilmaz M, Daver N, Borthakur G, DiNardo CD, Montalban-Bravo G, Short NJ, Valero YA, Jabbour E, Jain N, Pemmaraju N, Hammond D, Chien KS, Takahashi K, Issa GC, Abbas HA, Garcia-Manero G, Ravandi F, Kadia TM. A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. American Society of Hematology.
- Wang Z, Chen X, Sidoli S, Skwarska A, Jia Y, Yang L, Gupta V, Sharma S, Aifantis I, Abbas HA, Daver N, Tatarata QZ, Konopleva M. Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy. American Society of Hematology.
- Khouri IF, Kantarjian HM, Gulbis AM, Christopher MM, Haddad FG, Abbas HA, Wang B, Sasaki K, Jain N, Kadia TM, Marin D, Shpall EJ, Rondon G, Rafei H, Ramdial J, Im JS, Kebriaei P, Qiao W, Champlin RE, Jabbour E. Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial. American Society of Hematology.
- Marvin-Peek J, DiNardo CD, Jen W, Short NJ, Valero YA, Borthakur G, Daver N, Kugler E, Bazinet A, Abbas HA, Yilmaz M, Garcia-Manero G, Kantarjian HM, Kadia TM. Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax. American Society of Hematology.
- Forstén S, Penter L, Brück OE, Smolander J, Peltonen K, Lähdesmäki H, Kontro M, Porkka K, Abbas HA, Wu CJ, Huuhtanen J, Mustjoki S. Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes. American Society of Hematology.
- Veletic I, Manshouri T, Yin C, MD, Pacheco CD, Ly CP, Dasdemir E, Cohen EN, Masarova L, Pemmaraju N, Bose P, Kantarjian HM, Estrov Z, Reville PK, Dunbar A, Abbas HA. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. American Society of Hematology.
- Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Valero YA, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. American Society of Hematology.
- Wang B, Desai PN, Ku JJ, Daver N, Reville PK, Abbas HA. ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples. American Society of Hematology.
- Short NJ, Loghavi S, Yilmaz M, Karrar O, Jabbour JE, DiNardo CD, Kadia TM, Borthakur G, Issa GC, Abbas HA, Konopleva M, Ravandi F, Kantarjian HM, Daver N. Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor. American Society of Hematology.
- Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, McCall D, Pike A, Tan S, Kammerer B, Marshal A, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Abbas HA, Maiti A, Bazinet A, Jabbour E, Sasaki K, Borthakur G, Montalban-Bravo G, Jain N, Valero YA, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. American Society of Hematology.
- Jen W, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver N, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Pierce S, Kantarjian HM, Short NJ. Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. American Society of Hematology (ASH) Annual Meeting and Exposition.
- Vadakekolathu J, Skuli S, Boocock DJ, Coveney C, Ikpo EG, Wang B, Fenu EM, Abbas HA, Lai CE, Carroll MP, Rutella S. Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures. American Society of Hematology.
- Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi A, Gomez JA, Root JL, Reville PK, Quesada AE, Bueso-Ramos CE, Garcia MB, Burks JK, Abbas HA. Multimodal Spatial Profiling in Acute Myeloid Leukemia. American Society of Hematology.
- Marvin-Peek J, Kantarjian HM, Jen W, Borthakur G, Daver N, Maiti A, Short NJ, Kornblau SM, Pemmaraju N, Kugler E, Bazinet A, Valero YA, Abbas HA, Garcia-Manero G, Popat U, Shpall EJ, Ravandi F, DiNardo CD, Kadia TM. Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax. American Society of Hematology.
- Wang B, Root JL, Garza AI, Breaker J, Wierda WG, Abbas HA, Reville PK. Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD. American Society of Hematology.
- Khasawneh A, Paran FJ, Maiti A, Wang B, Hayes K, DiNardo CD, Andreeff M, Abbas HA, Konopleva M, Tabe Y. Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients. American Society of Hematology.
- Wang Z, Skwarska A, Poigailwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou E, Bhalla KN, Zhou D, Mead AJ, Rampal R, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva M. Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML. American Society of Hematology.
- Kugler E, Loghavi S, Ravandi F, DiNardo CD, Daver N, Kadia TM, Borthakur G, Issa GC, Abbas HA, Bose P, Senapati J, Kantarjian HM, Short NJ. Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis. American Society of Hematology.
- Marvin-Peek J, Jen W, Short NJ, Issa GC, MD, Yilmaz M, Montalban-Bravo G, Bazinet A, Sasaki K, Maiti A, Borthakur G, Hammond D, Chien KS, Abbas HA, Pemmaraju N, Garcia-Manero G, Jabbour E, Ravandi F, Kadia TM, Daver N, DiNardo CD. Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease. American Society of Hematology.
- Majid D, WANG Z, Yuan B, Yassouf MY, Schalk A, Gamal BT, Tatarata QZ, Root JL, Garza AI, Nguyen AH, Ferri-Borgogno S, Reville PK, Lavie A, Abbas HA. Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia. American Society of Hematology.
- Marvin-Peek J, Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, Lachowiez CA, Valero YA, Montalban-Bravo G, Sasaki K, Haddad FG, Issa GC, Masarova L, Abbas HA, Andreeff M, Borthakur G, Mullin J, Tippett GD, Chien KS, Hammond D, Ishizawa J, Jain N, Reville PK, Swaminathan M, Yilmaz M, Daver N, Kadia TM, Ravandi F, Garcia-Manero G, Kantarjian HM, DiNardo CD. Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. American Society of Hematology.
- Abbas HA, Wang B, Marvin-Peek J, Yuan B, Garza AI, Root JL, Arruda A, Liu Y, DiNardo CD, Kadia TM, Daver N, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Reville PK. Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker. American Society of Hematology.
- Karrar O, Jabbour E, Senapati J, Haddad FG, Issa GC, Sasaki K, Abbas HA, Dellasala SE, Ravandi F, Kantarjian HM, Short NJ. A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse. American Society of Hematology.
- Bazinet A, Garcia-Manero G, Bataller A, Valero YA, Yilmaz M, Jabbour E, Montalban-Bravo G, Pemmaraju N, Issa GC, Short NJ, Kadia TM, Jain N, Masarova L, Daver N, Hammond D, Borthakur G, Maiti A, Takahashi K, Chien KS, Kornblau SM, Abbas HA, Ohanian M, Senapati J, DiNardo CD, Kantarjian HM, Ravandi F. Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy. American Society of Hematology.
- Bouligny IM, Kantarjian HM, Yilmaz M, Daver N, Borthakur G, DiNardo CD, Montalban-Bravo G, Short NJ, Valero YA, Jain N, Pemmaraju N, Hammond D, Chien KS, Takahashi K, Issa GC, Abbas HA, Jabbour E, Garcia-Manero G, Ravandi F, Kadia TM. Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine. American Society of Hematology.
- Swaminathan M, Abbas HA, Garcia-Manero G, Daver N, Kadia TM, DiNardo CD, Borthakur G, Jabbour E, Pemmaraju N, Valero YA, Ohanian M, Jain N, Short NJ, Bose P, Takahashi K, Hwang H, Huang X, Edelkamp Jr P, Pierce S, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Ravandi F. Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods. American Society of Hematology.
- Croden J, Hammond D, Chien KS, Maiti A, Tippett GD, Montalban-Bravo G, Morales M, Short NJ, Abbas HA, Issa GC, Kadia TM, Borthakur G, Ravandi F, DiNardo CD. Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. American Society of Hematology.
- Senapati J, DiNardo CD, Kadia TM, Khaire NS, Haddad FG, Loghavi S, Tang G, Deshmukh I, Jabbour JE, Issa GC, Short NJ, Yilmaz M, Hammond D, Borthakur G, Abbas HA, Bazinet A, Pierce S, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver N. Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy. American Society of Hematology.
- Arani N, Jen W, Bataller A, Bazinet A, Ravandi F, Daver N, Takahashi K, Loghavi S, Abbas HA, Almanza E, Montalban-Bravo G, Garcia-Manero G, DiNardo CD, Kantarjian HM, Kadia TM. Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia. American Society of Hematology.
- Short NJ, Ravandi F, Daver N, DiNardo CD, Borthakur G, Kadia TM, Yilmaz M, Issa GC, Abramova R, Garza AI, Kantarjian HM, Abbas HA. A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress. American Society of Hematology (ASH) Annual Meeting and Exposition.
- Arora S, Senapati J, Loghavi S, Reville PK, Wang B, Kadia TM, DiNardo CD, Pemmaraju N, Yilmaz M, Jabbour JE, Short NJ, Montalban-Bravo G, Maiti A, Tang G, Sasaki K, Borthakur G, Alvarez J, Pierce S, Nogueras González GM, Ning J, Issa GC, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA, Daver N. Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse. American Society of Hematology.
- Dasdemir E, Veletic I, Ly CP, Quesada AE, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar AJ, Wani KM, Antunes DA, Reville PK, Gunaratne P, Tower RJ, Sharma P, Abbas HA. Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia. American Society of Hematology.
- Azevedo RS, Kantarjian HM, Takahashi K, Nasnas CC, Loghavi S, Jain N, Haddad FG, Senapati J, Issa GC, Abbas HA, Kadia TM, Chien KS, Montalban-Bravo G, Garris R, Ravandi F, Jabbour E, Short NJ. Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia. American Society of Hematology.
- Sajedi S, Short NJ, Dasdemir E, Wang B, Nasnas C, Jabbour E, Kantarjian HM, Reville PK, Abbas HA. Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin. American Society of Hematology.
- Arora S, Yilmaz M, Jen W, Short NJ, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Deshmukh I, Issa GC, Jabbour JE, Pemmaraju N, Andreeff M, Takahashi K, Bhalla KN, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver N. Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations. American Society of Hematology.
- Reville PK, Sajedi S, Ferrajoli A, Burger JA, Keating MJ, Garg N, Deng Q, Green MR, Abbas HA, Wierda WG, Jain N. Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL. American Society of Hematology.
- Houri A, Abbas HA, Abdallah A. The role of Natural Reserves in Awareness Raising and Biodiversity Conservation.
- Houri A, el-Jeblawi S, Hammoud M, Abbas HA. Effect of Current Culture of Water Use on Coastal River Water Quality in Lebanon.
Book Chapters
- Abbas HA, Saab R. Premalignancy and Cellular Senescence. In: Tumor Dormancy, Quiescence, and Senescence, Volume 2. Springer, 195-206, 2013.
Books (edited and written)
- Abbas HA, Houri AF. In: Student's Guide to Graduate School, First. Self Publish, 2011.
Selected Presentations & Talks
Local Presentations
- 2024. Dissecting Acute Myeloid Leukemia: Insights from Single-Cell Epigenetic Accessibility and Immune Repertoires. Invited. GCC Single Cell Omics Symposium. Houston, Texas, US.
- 2024. Cellular Hierarchies in Acute Myeloid Leukemia: Clinical Applications. Conference. Center for Epigenetics Retreat. Houston, TX, US.
- 2024. Prognosticating AML Outcomes: Insights from Blood-based Proteomic Testing. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2024. AML, Interferon Gamma and the Immune System: An Unlikely Conversation. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2023. CD8 T Cells and Interferon Gamma in Acute Myeloid Leukemia: Friends or Foes?. Conference. MD Anderson Cancer Center, Zeev Estrov Leukemia Research Conference. Houston, TX, US.
- 2023. Physician Scientist/K12 Scholar Quarterly Dinner. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2023. Choosing and Working with a Mentor. Conference. Research Curriculum for the DoCM Hem/Onc Fellows, MD Anderson Cancer Center. Houston, TX, US.
- 2022. Pipelines for Supporting Clinical Trials, Tracking Cancer, Addiction & Fossil Fuels. Conference. University of Houston College of Natural Sciences and Mathematics. Houston, TX, US.
- 2022. Dissecting Acute Myeloid Leukemia and its Microenvironment, One Cell at a Time. Invited. School of Biomedical Informatics. Houston, TX, US.
- 2022. Multimodal Assessment of Acute Myeloid Leukemia: Functional Genomics, Single Cell Profiling and Beyond. Invited. University of Houston. Houston, TX, US.
- 2022. Expert Discussant. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2022. Faculty Panel Discussion Speaker. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2022. Graduate Medical Education Competency Series " Code Status". Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2022. Investigating Acute Myeloid Leukemia: From Clinical Studies to Multi-Omic Single Cell Profiling. Invited. School of Biomedical Informatics Research Seminar series. Houston, TX, US.
- 2021. Investigating Acute Myeloid Leukemia: From Clinical Studies to Single Cell Analysis. Invited. University of Texas School of Public Health Seminar Series, TX, US.
- 2021. Introduction to Research Opportunities Seminar Series “Leukemia Research”. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2021. T32 Research Seminar Series title “Mining the AML Ecosystem: A Tale of 8 Patients”. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2021. Graduate Medical Education Competency Series “Discussing Code Status in the Middle of the Night (and at more opportune times)”. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2021. “Single Cell Profiling Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy in Acute Myeloid Leukemia”. Conference. MD Anderson Research Townhall Meeting. Houston, TX, US.
- 2021. Single Cell Profiling of AML Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy.”. Conference. MD Anderson Research Townhall Meeting. Houston, TX, US.
- 2020. Single Cell Profiling of AML Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy. Conference. MD Anderson Research Townhall Meeting. Houston, TX, US.
- 2020. Single Cell Profiling of AML Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy”. Conference. MD Anderson Research Townhall Meeting. Houston, TX, US.
- 2010. The consequences of disrupting the Mdm2-p53 pathway in hematopoiesis and its niche. Invited. Institute of Molecular Medicine Research Exchange lecture Series. Houston, TX, US.
Regional Presentations
- 2023. Cellular Hierarchies in Acute Myeloid Leukemia. Conference. MD Anderson Cancer Center, US.
- 2023. Research Approaches in Myeloid Neoplasm. Conference. The University of Texas MD Anderson Cancer Center, US.
- 2023. Integrative Multiomic Approaches to Overcoming Challenges in AML Research. Conference. MD Anderson Cancer Center, US.
- 2021. “Single-cell characterization of AML patients receiving PD-1-based therapy”. Conference. TxSCO Annual Meeting, TX, US.
- 2019. RNA and flow-based Immune Assessments in Azacitidne and Nivolumab-treated Relapse/Refractory Acute Myeloid Leukemia (AML) Patients: A subset analysis a Phase 2 Study. Conference. British Columbia, US.
National Presentations
- 2024. Comprehensive Profiling of 200+ Proteins Using the NULISAseq Inflammation Panel Reveals Unique Signatures of Immune Response in AML. Conference, US.
- 2024. Development of a blood-based protein signature for AML,. Conference. Houston, TX, US.
- 2024. A New Era of Discovery Power: From comprehensive microenvironment characterization to multiomics liquid biopsy. Invited. San Diego, CA, US.
- 2023. Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance. Conference. San Diego, CA, US.
- 2023. Unveiling Clinical Outcomes of Acute Myeloid Leukemia Through Single-Cell Exploration. Conference. Illumina Usergroup Summit. Houston, TX, US.
- 2023. Dissecting CD8 T cells in Acute Myeloid Leukemia, Cell by Cell. Conference, US.
- 2020. Single Cell Profiling Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy in Acute Myeloid Leukemia. Conference. Houston, TX, US.
- 2020. Single Cell Profiling Reveals a CD8+ Continuum and Adaptive T Cell Plasticity in Response to PD-1 Blockade-based Therapy in Acute Myeloid Leukemia. Conference, US.
- 2020. Single-cell profiling of Acute Myeloid Leukemia and its Microenvironment Reveals a CD8+ Continuum and Adaptable T Cell Plasticity in Response to PD-1 Blockade-based Therapy. Conference, US.
International Presentations
- 2025. Multiple Proteins Correlate With Tryptase Levels in Patients With Indolent Systemic Mastocytosis (ISM): Preliminary Results of Plasma Proteomic Analysis in PIONEER. Poster. San Diego, US.
- 2025. Avapritinib Impacts the Plasma Inflammatory Proteome in Patients With Indolent Systemic Mastocytosis (ISM). San Diego, US.
- 2024. Investigating the Versatility and Clinical Significance of Oncology and Autoimmune Pathological Application in Modern Medicine – Panel Discussion. Conference. Dubai, AE.
- 2024. Current standard guidelines in the region, challenges and opportunities for implementing precision oncology – Panel Discussion. Conference. Dubai, AE.
- 2024. Insights from Genomic Profiling of Leukemias for Precision Medicine and Targeted Therapeutics,. Conference. Dubai, AE.
- 2024. The Power of Single-Cell Analysis in Translational Research. Conference. Dubai, AE.
- 2024. Management of Acute Myeloid Leukemia. Invited. Regional Haematology Blood/Journal Club. Auckland, NZ.
- 2024. Dissecting AML-Immune Cells Cross Talk, Department of Biomedical Research. Invited, CH.
- 2024. Dissecting AML-Immune Cell Crosstalk. Invited. Nottingham, GB.
- 2024. Mutation patterns and Prognostic implications in Acute Myeloid Leukemia with chromosomal 7 deletions. Conference. Madrid, ES.
- 2015. Empowering your medical career track: What’s beyond Academia and Residency Career Tracks?. Invited, LB.
- 2013. Basics of Medical Writing” LeMSIC SCORE Research Workshop. Invited. Beirut, LB.
- 2012. Case Reports: Severe mucositis with tongue shedding, Novel HBB Mutations and Rare Pitt-Hopkin’s Syndrome. Invited. Beirut, LB.
- 2012. An Open Label Phase II Clinical Trial on Beta Thalassemia intermedia with HQK-1001. Invited. Beirut, LB.
- 2012. Sickle Cell Disease: A Genetics Perspective. Invited. Beirut, LB.
- 2012. The Process of Pursuing Graduate Studies Abroad. Invited. Byblos, LB.
- 2012. Sickle Cell Disease: A Genetics Perspective and An Open Label Phase II Study of HQK-1001 in Subjects with beta-Thalassemia Intermedia. Invited. Beirut, LB.
- 2012. Multi Center Screening Programs: Anemia, Iron Deficiency Anemia and Lead Poisoning, and Neonatal Screening Programs for Sickle Cell Disease in Public Hospitals Across Lebanon. Invited. Beirut, LB.
- 2011. p53: Genetic Models and its role in hematopoiesis. Invited. Beirut, LB.
- 2011. p53: a Tumor Suppressor, but a Hematopoiesis Depressor. Invited. Beirut, LB.
- 2010. p53: A guardian of your genome, but a killer of blood cells. Invited. Byblos, LB.
Grant & Contract Support
| Date: | 2025 - 2029 |
| Title: | Organoid-Based Modeling and Therapeutic Targeting of TP53-Mutated Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) - Peer Reviewed Cancer Research Program |
| Role: | PI |
| ID: | FP#00023601 |
| Date: | 2025 - 2028 |
| Title: | Exploiting synthetic lethalities between HNRNPK loss and ribosomal dysfunction in del9q AML |
| Funding Source: | CPRIT - IIRA |
| Role: | Co-I |
| ID: | FP00019697_Res1 |
| Date: | 2025 - 2026 |
| Title: | Establishing a Leukemia Immune Microenvrionment (LIME) Platform for Advancing Therapeutic Discoveries |
| Funding Source: | Marshall Foundation Funding |
| Role: | PI |
| ID: | AWD#00007359 |
| Date: | 2024 - 2027 |
| Title: | Study the effect of co-targeting AML by CD123-directed NK cells and BCL-2 inhibition |
| Funding Source: | Department of Defense (DoD), Rare Cancer Research Program, Idea Development Award |
| Role: | Other Significant Contributor |
| ID: | RA#230262 |
| Date: | 2024 - 2025 |
| Title: | Venetoclax Resistance in Acute Myeloid Leukemia: The Role of Inflammation and Stromal Interactions |
| Funding Source: | MD Anderson Cancer Center Seed Funding |
| Role: | PI |
| ID: | RCTS#64247 |
| Date: | 2024 - 2026 |
| Title: | Structure-guided cancer immunotherapy design with HLA-Arena and CrossDome |
| Funding Source: | National Institute of Health |
| Role: | Co-I |
| ID: | FP#19775 |
| Date: | 2024 - 2025 |
| Title: | Decoding Immune Dysregulation for Targeted Therapeutic Strategies in Acute Myeloid Leukemia |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | AWD#8392 |
| Date: | 2024 - 2027 |
| Title: | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240287 |
| Date: | 2023 - 2027 |
| Title: | Multimodal Characterization of the Tumor Immune Microenvironment and Metabolic States in Pediatric and AYA Acute Myeloid Leukemia |
| Funding Source: | Pediatric Team Funding - MD Anderson Cancer Center |
| Role: | Co-PI |
| ID: | ID125466 |
| Date: | 2022 - 2027 |
| Title: | Understanding the Tumor Immune Microenvironment of Myeloid Neoplasms in context of Chemo and Immunotherapies |
| Funding Source: | MD Anderson Institutional Start-Up Grant |
| Role: | PI |
| ID: | ID#123805 |
| Date: | 2022 - 2027 |
| Title: | Determine the epigenetic and immune regulators of chromosome 7/7q in AML |
| Funding Source: | Physician Scientist Award |
| Role: | PI |
| ID: | ID#123805 |
| Title: | Other Philanthropy |
| Funding Source: | Multiple Sources |
| Role: | PI |
| Title: | Donation from the Diego Oslo Family to Support Abbas Lab Research |
| Funding Source: | Diego Oslo Fund (Patient Donation) |
| Role: | PI |
Patient Reviews
CV information above last modified May 01, 2025